Home › NDC Lookup › RxCUI directory › RxCUI 2594762

Ranolazine 500 MG Oral Granules [Aspruzyo] — RxCUI 2594762

RxNorm drug concept · Semantic branded drug
RxCUI 2594762 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2594762
Official nameRanolazine 500 MG Oral Granules [Aspruzyo]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asAspruzyo 500 MG Oral Granules; ASPRUZYO Sprinkle 500 MG Oral Granules
FDA products mapped1
Package NDCs mapped3
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ranolazine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Ranolazine is specifically for chronic angina — the recurring chest pain or tightness you get when your heart isn't getting enough blood flow. It's not a heart attack treatment or...
  • What exactly is ranolazine supposed to do for me?
  • If you're taking the extended-release tablet (Ranexa or generic ranolazine), you can take it with or without food — your choice. The important thing is to swallow it whole. Never c...
  • Do I have to take this with food? And can I split the tablet?
📖 Read our full Ranolazine guide →

🕸️ Concept Web — How Ranolazine 500 MG Oral Granules [Aspruzyo] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Ranolazine 500 MG Oral Granules [Aspruzyo] RxCUI 2594762

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Ranolazine 35829
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Aspruzyo 2594754
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ranolazine Oral Granules 2594752
    • Ranolazine Granule Product 2594751
    • Ranolazine Oral Product 1157902
    • Ranolazine Oral Granules [Aspruzyo] 2612257
    • Aspruzyo Granule Product 2594757
    • Aspruzyo Oral Product 2594756
    • Oral Granules 317690
    • Granule Product 1294708
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Ranolazine 500 MG Oral Granules SCD · 2594760
  • Ranolazine 500 MG SCDC · 616490
  • Ranolazine Oral Granules SCDF · 2594752
  • Ranolazine Granule Product SCDG · 2594751
  • Ranolazine Oral Product SCDG · 1157902

Brand-Name Concepts

  • Ranolazine 500 MG [Aspruzyo] SBDC · 2612254
  • Ranolazine Oral Granules [Aspruzyo] SBDF · 2612257
  • Aspruzyo Granule Product SBDG · 2594757
  • Aspruzyo Oral Product SBDG · 2594756
  • Aspruzyo BN · 2594754

📦 FDA Products & Package NDCs

1 product · 3 package NDCs
3 package NDCs map to RxCUI 2594762 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
47335-0625-11 1 GRANULE in 1 PACKET (47335-625-11) ASPRUZYO SPRINKLE SUN PHARMACEUTICAL INDUSTRIES, INC. 2022-02-28
47335-0625-30 30 GRANULE in 1 CARTON (47335-625-30) ASPRUZYO SPRINKLE SUN PHARMACEUTICAL INDUSTRIES, INC. 2022-02-28
47335-0625-60 60 GRANULE in 1 CARTON (47335-625-60) ASPRUZYO SPRINKLE SUN PHARMACEUTICAL INDUSTRIES, INC. 2022-02-28
Observed labelers: SUN PHARMACEUTICAL INDUSTRIES, INC. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.